CDK1
Cyclin-dependent kinase 1
As of the edition of 20 October 2026, CDK1 (cyclin-dependent kinase 1, UniProt P06493) has 10 drugs tested at it and 14 companies on the list, 13 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P06493
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 14
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Digestive system; Skin and connective tissue; Inherited and neonatal; Hormones
- Registered trials of its drugs
- 113
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 2 |
| Stopped | 8 |
| Total | 10 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Alvocidib | Stopped | Phase 2 | none listed |
| Dinaciclib | Stopped | Phase 3 | none listed |
| Riviciclib | Went quiet | Phase 2 | none listed |
| Seliciclib | Stopped | Phase 2 | none listed |
| Zotiraciclib | Stopped | Phase 2 | none listed |
| Milciclib | Stopped | Phase 2 | none listed |
| AG-24322 | Stopped | Phase 1 | none listed |
| RG-547 | Went quiet | Phase 1 | none listed |
| RGB-286638 | Stopped | Phase 1 | none listed |
| TP-1287 | Stopped | Phase 1 | none listed |
10 of 10 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 13 |
| Engaged | 1 |
| Total on the list | 14 |
| Company | Route |
|---|---|
| Merck & Co. | Route A |
| Sanofi | Route A |
| AbbVie | Route A |
The other 11 companies at CDK1
In the product14 companies in all; 11 are not named here, and no score is.
See the 14 companies at CDK1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.